Virpax Pharmaceuticals said that it has acquired exclusive North American rights to Nanomerics' MMS019 nasal powder, which it calls a "high density molecular masking spray" and which is intended to block viruses from taking hold in the respiratory tract. Virpax said that MMS019 is in preclinical development for the prevention of COVID-19, seasonal flu, and other … [Read more...] about Virpax licenses Nanomerics’ MM2019 “molecular masking” nasal powder
News
Lupin’s generic version of ProAir HFA approved by the FDA
The FDA has approved Lupin's generic version of Teva's ProAir HFA albuterol MDI for the treatment of asthma, the company said. Lupin said that it will manufacture the inhaler at its facility in Indore, India. Lupin CEO Vinita Gupta commented, “Approval of our generic albuterol MDI is a significant milestone in our complex generics evolution and a validation of … [Read more...] about Lupin’s generic version of ProAir HFA approved by the FDA
Medical Developments International buys back European Union rights to Penthrox inhaler from Mundipharma
Medical Developments International (MVP) has announced that it will buy back the European Union rights to its Penthrox methoxyflurane inhaler from Mundipharma for €3 million, plus a 5% royalty up to a maximum of €5 million. The companies plan a 6-month transition period beginning September 1, 2020. Penthrox is approved throughout Europe for the emergency treatment … [Read more...] about Medical Developments International buys back European Union rights to Penthrox inhaler from Mundipharma
Verona initiates Phase 2b trial of ensifentrine MDI for COPD
Verona Pharma has announced the initiation of a Phase 2b trial of its ensifentrine MDI for the treatment of COPD in the UK, with results expected in the first half of 2021. In March 2020, Verona announced positive results from a Phase 2a trial of the MDI and noted that the second part of the trial would be delayed due to the COVID-19 pandemic. The Phase 2b trial … [Read more...] about Verona initiates Phase 2b trial of ensifentrine MDI for COPD
Lannett gets rights to distribute Respirent’s generic Flovent Diskus in the US
According to Lannett, the company has signed an agreement with Chinese inhaled drug developer Respirent for exclusive rights to distribute Respirent's generic version of GSK's Flovent Diskus fluticasone propionate DPI, which is in early development. In October 2019, Lannett announced a US distribution deal with Respivent for that company's generic version of GSK's … [Read more...] about Lannett gets rights to distribute Respirent’s generic Flovent Diskus in the US
United Therapeutics submits sNDA for use of Tyvaso in PH-ILD
The FDA has accepted a supplemental NDA for United Therapeutics's Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), the company said. In February 2020, United Therapeutics announced that the Phase 3 INCREASE study of Tyvaso in PH-ILD patients had met its primary endpoint. Tyvaso … [Read more...] about United Therapeutics submits sNDA for use of Tyvaso in PH-ILD
Union Therapeutics acquires option for TFF’s dry powder niclosamide
Danish pharma company Union Therapeutics has entered into an agreement with TFF Pharmaceuticals for an option to license TFF's dry powder niclosamide, the companies announced. The deal includes potential inhaled and oral formulations of niclosamide for the treatment of COVID-19 and is worth up to $210 million in milestone payments as well as royalties on any … [Read more...] about Union Therapeutics acquires option for TFF’s dry powder niclosamide
Proveris Scientific announces two appointments
Aerosol testing company Proveris Scientific has announced two new appointments: Joseph Werbeck rejoins the company as Senior Director of Technical Service and Mohamed Eldam joins Proveris as Applications Chemist. Werbeck, who will report to VP of Technical Service Alberto Correia, served as Director of Technical Service at Proveris from 2014-2018 before leaving for a … [Read more...] about Proveris Scientific announces two appointments
AstraZeneca increases production of FluMist Quadrivalent for 2020-2021 flu season
AstraZeneca has announced that the first doses of its FluMist Quadrivalent live intranasal flu vaccine for the 2020-2021 US influenza season have shipped. FluMist Quadrivalent is approved for use in children over the age of 2 and adults up to age 49. The company said that it has increased planned production of the vaccine by more than 25% in response to … [Read more...] about AstraZeneca increases production of FluMist Quadrivalent for 2020-2021 flu season
TFF Pharmaceuticals raises almost $26 million
TFF Pharmaceuticals announced that the company has raised $25.9 million in a private placement, with the funds to be used to "to accelerate the expansion of the company’s internal development portfolio beyond its programs for voriconazole and tacrolimus inhalation powders." Earlier this year, the company announced that it was working on a universal flu vaccine in … [Read more...] about TFF Pharmaceuticals raises almost $26 million